Literature DB >> 34325666

Vedolizumab combined with surgical resection successfully treated perforating Crohn's disease with peritoneal space to rectal and vaginal fistulas: a case report.

Meng-Wu Chung1, Chien-Ming Chen2, Jun-Te Hsu3, Ren-Chin Wu4, Cheng-Tang Chiu5,6, Chia-Jung Kuo5,6, Ming-Yao Su6,7, Puo-Hsien Le8,9,10.   

Abstract

BACKGROUND: Intestinal perforations and fistulas are common complications of Crohn's disease. However, chronic perforation with peritoneal space to rectal and vaginal fistulas have not been previously reported. CASE
PRESENTATION: A 38-year-old female suffered from progressive lower abdominal pain, diarrhea and weight loss. Terminal ileal chronic perforation with intra-abdominal abscess, peritoneal space to rectal and vaginal fistulas were noted. The patient received surgical resection of the cecum and terminal ileum, and then vedolizumab treatment. Three months later, she had complete fistula closure, and her body mass index had increased from 13 to 22.
CONCLUSION: Vedolizumab combined with stool diversion is effective at treating Crohn's disease with chronic perforation and complex peritoneal space to rectal and vaginal fistulas.
© 2021. The Author(s).

Entities:  

Keywords:  Crohn’s disease; Fistula; Perforation; Surgery; Vedolizumab

Year:  2021        PMID: 34325666     DOI: 10.1186/s12876-021-01875-6

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  1 in total

1.  [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].

Authors:  Piotr Rozpondek; Małgorzata Zwolińska-Wcisło; Magdalena Przybylska; Tomasz Mach
Journal:  Przegl Lek       Date:  2011
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.